Medication Transition: Discontinuing Dulero and Stiolto When Switching to Trelegy Ellipta
Direct Answer
Yes, the patient must stop both Dulero and Stiolto Respimat immediately when switching to Trelegy Ellipta to avoid dangerous medication duplication and excessive bronchodilator exposure. 1
Why Discontinuation is Mandatory
Medication Overlap Creates Dangerous Duplication
Trelegy Ellipta already contains all the bronchodilator classes present in both Dulero and Stiolto:
- Trelegy Ellipta components: Fluticasone (ICS) + Umeclidinium (LAMA) + Vilanterol (LABA) 2
- Dulero components: Formoterol (LABA) + Aclidinium (LAMA) 3
- Stiolto Respimat components: Tiotropium (LAMA) + Olodaterol (LABA) 4, 5
Continuing both medications would result in:
- Double LAMA exposure (Umeclidinium + Aclidinium + Tiotropium)
- Double LABA exposure (Vilanterol + Formoterol + Olodaterol)
- Increased cardiovascular risk from excessive β-agonist stimulation 6
- Increased anticholinergic side effects (dry mouth, urinary retention, confusion) 7
Evidence Supporting Single Triple Therapy
Triple therapy should be delivered as a single regimen, not by combining multiple dual therapies. The GOLD guidelines specifically recommend LAMA/LABA/ICS combinations as integrated treatment strategies, not additive combinations of separate dual bronchodilators 1. The IMPACT study demonstrated that single-inhaler triple therapy (like Trelegy) provides superior outcomes compared to dual therapies while maintaining safety 2.
Implementation Strategy
Immediate Actions Required
Stop both medications on the same day Trelegy is initiated:
- Discontinue Dulero (Formoterol/Aclidinium) completely 6
- Discontinue Stiolto Respimat (Tiotropium/Olodaterol) completely 4
- Begin Trelegy Ellipta once daily 2
No tapering or overlap period is necessary because all three medications contain long-acting bronchodilators that provide 24-hour coverage, ensuring no gap in bronchodilation during the transition 7.
Monitoring After Transition
Assess treatment response at specific intervals:
- 1 month: Check for adequate symptom control and proper inhaler technique 8
- 6 months: Evaluate exacerbation rate, CAT score, and quality of life measures 8, 9
- 12 months: Determine if triple therapy continues to provide benefit; if not, consider de-escalation 8
Monitor for pneumonia risk given ICS component in Trelegy, especially if patient has risk factors: current smoking, age ≥55 years, BMI <25 kg/m², or history of prior pneumonia 6.
Common Pitfalls to Avoid
Never continue dual bronchodilator combinations alongside triple therapy. This represents the most common prescribing error when transitioning COPD patients and significantly increases adverse event risk without additional therapeutic benefit 1.
Do not use short-acting bronchodilators as "bridge therapy" during the transition—Trelegy provides immediate 24-hour bronchodilation from day one 2. Rescue short-acting bronchodilators (albuterol/salbutamol) remain appropriate for breakthrough symptoms only 1.
Ensure the patient understands this is a complete medication switch, not an addition. Patient confusion about continuing old inhalers while starting new ones is a frequent cause of medication duplication 6.